{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:35:03Z","timestamp":1793907303208,"version":"4.8.0"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pneumocystis jirovecii pneumonia (PCP) causes substantive morbidity in immunocompromised patients. The EORTC\/MSGERC convened an expert group to elaborate consensus definitions for Pneumocystis disease for the purpose of interventional clinical trials and epidemiological studies and evaluation of diagnostic tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Definitions were based on the triad of host factors, clinical-radiologic features, and mycologic tests with categorization into probable and proven Pneumocystis disease, and to be applicable to immunocompromised adults and children without human immunodeficiency virus (HIV). Definitions were formulated and their criteria debated and adjusted after public consultation. The definitions were published within the 2019 update of the EORTC\/MSGERC Consensus Definitions of Invasive Fungal Disease. Here we detail the scientific rationale behind the disease definitions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The diagnosis of proven PCP is based on clinical and radiologic criteria plus demonstration of P. jirovecii by microscopy using conventional or immunofluorescence staining in tissue or respiratory tract specimens. Probable PCP is defined by the presence of appropriate host factors and clinical-radiologic criteria, plus amplification of P. jirovecii DNA by quantitative real-time polymerase chain reaction (PCR) in respiratory specimens and\/or detection of \u03b2-d-glucan in serum provided that another invasive fungal disease and a false-positive result can be ruled out. Extrapulmonary Pneumocystis disease requires demonstration of the organism in affected tissue by microscopy and, preferably, PCR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These updated definitions of Pneumocystis diseases should prove applicable in clinical, diagnostic, and epidemiologic research in a broad range of immunocompromised patients without HIV.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciaa1805","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T04:28:21Z","timestamp":1606883301000},"page":"S114-S120","source":"Crossref","is-referenced-by-count":153,"title":["<i>Pneumocystis jirovecii<\/i>Disease: Basis for the Revised EORTC\/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus"],"prefix":"10.1093","volume":"72","author":[{"given":"Katrien","family":"Lagrou","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium"},{"name":"Department of Laboratory Medicine and National Reference Centre for Mycosis, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Chen","sequence":"additional","affiliation":[{"name":"Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital and the University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Masur","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Viscoli","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Genoa (DISSAL) and Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine F","family":"Decker","sequence":"additional","affiliation":[{"name":"Infectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Pagano","sequence":"additional","affiliation":[{"name":"Istituto di Ematologia, Policlinico Universitario A. Gemelli\u2013IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H","family":"Groll","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology and Oncology, University Children\u2019s Hospital Muenster, Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"2021063009510467900_CIT0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2021063009510467900_CIT0002","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021063009510467900_CIT0003","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/cid\/ciu911","article-title":"Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group","volume":"60","author":"Herbrecht","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021063009510467900_CIT0004","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2021063009510467900_CIT0005","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2021063009510467900_CIT0006","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2021063009510467900_CIT0007","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2021063009510467900_CIT0008","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/cid\/cix198","article-title":"Pharmacodynamics of isavuconazole for invasive mold disease: role of galactomannan for real-time monitoring of therapeutic response","volume":"64","author":"Kovanda","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021063009510467900_CIT0009","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2021063009510467900_CIT0010","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u2013 2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2021063009510467900_CIT0011","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3201\/eid1710.110087","article-title":"Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001\u20132006","volume":"17","author":"Park","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"2021063009510467900_CIT0012","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/tid.12186","article-title":"Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"16","author":"Kauffman","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"2021063009510467900_CIT0013","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","author":"Donnelly","year":"2020"},{"key":"2021063009510467900_CIT0014","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-100-5-663","article-title":"Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies","volume":"100","author":"Kovacs","year":"1984","journal-title":"Ann Intern Med"},{"key":"2021063009510467900_CIT0015","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1164\/ajrccm\/140.5.1204","article-title":"Pneumocystis carinii pneumonia: differences in lung parasite number and inflammation in patients with and without AIDS","volume":"140","author":"Limper","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"2021063009510467900_CIT0016","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/cc6806","article-title":"Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection [published correction appears in Crit Care 2009; 13(2)407]","volume":"12","author":"Monnet","year":"2008","journal-title":"Crit Care"},{"key":"2021063009510467900_CIT0017","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/jac\/dkp372","article-title":"Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study","volume":"64","author":"Helweg-Larsen","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2021063009510467900_CIT0018","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00408-009-9214-y","article-title":"Radiological features of Pneumocystis jirovecii pneumonia in immunocompromised patients with and without AIDS","volume":"188","author":"Hardak","year":"2010","journal-title":"Lung"},{"key":"2021063009510467900_CIT0019","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2169\/internalmedicine.49.2871","article-title":"Comparison of clinical and radiological features of Pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study","volume":"49","author":"Tasaka","year":"2010","journal-title":"Intern Med"},{"key":"2021063009510467900_CIT0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3109\/00365549709035900","article-title":"Pneumocystis carinii colonization in the absence of immunosuppression","volume":"29","author":"Armbruster","year":"1997","journal-title":"Scand J Infect Dis"},{"key":"2021063009510467900_CIT0021","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/thorax.58.7.594","article-title":"Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study","volume":"58","author":"Maskell","year":"2003","journal-title":"Thorax"},{"key":"2021063009510467900_CIT0022","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/CMR.00013-12","article-title":"Colonization by Pneumocystis jirovecii and its role in disease","volume":"25","author":"Morris","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2021063009510467900_CIT0023","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N Engl J Med"},{"key":"2021063009510467900_CIT0024","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1542\/peds.61.1.35","article-title":"Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children","volume":"61","author":"Pifer","year":"1978","journal-title":"Pediatrics"},{"key":"2021063009510467900_CIT0025","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1086\/319340","article-title":"Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants","volume":"32","author":"Vargas","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2021063009510467900_CIT0026","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12281-010-0029-3","article-title":"Pneumocystis jirovecii pneumonia: current knowledge and outstanding public health issues","volume":"4","author":"Harris","year":"2010","journal-title":"Curr Fungal Infect Rep"},{"key":"2021063009510467900_CIT0027","first-page":"283","article-title":"Current issues in the epidemiology, transmission, and reactivation of Pneumocystis carinii","volume":"13","author":"Hughes","year":"1998","journal-title":"Semin Respir Infect"},{"key":"2021063009510467900_CIT0028","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1128\/CMR.10.3.401","article-title":"Extrapulmonary pneumocystosis","volume":"10","author":"Ng","year":"1997","journal-title":"Clin Microbiol Rev"},{"key":"2021063009510467900_CIT0029","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1086\/517633","article-title":"AIDS-associated atypical Pneumocystis carinii pneumonia revisited","volume":"26","author":"Groll","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2021063009510467900_CIT0030","doi-asserted-by":"crossref","first-page":"A38","DOI":"10.1055\/s-2001-17501","article-title":"[Guidelines for prevention of Pneumocystis carinii pneumonitis in children and adolescents with cancer.]","volume":"213","author":"Groll","year":"2001","journal-title":"Klin Padiatr"},{"key":"2021063009510467900_CIT0031","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1172\/JCI119384","article-title":"The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung","volume":"99","author":"Limper","year":"1997","journal-title":"J Clin Invest"},{"key":"2021063009510467900_CIT0032","first-page":"330","article-title":"Lymphocytes in host defense against Pneumocystis carinii.","volume":"13","author":"Beck","year":"1998","journal-title":"Semin Respir Infect"},{"key":"2021063009510467900_CIT0033","doi-asserted-by":"crossref","first-page":"a019828","DOI":"10.1101\/cshperspect.a019828","article-title":"Pneumocystis","volume":"4","author":"Gigliotti","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2021063009510467900_CIT0034","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V96.2.754","article-title":"Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults","volume":"96","author":"Mackall","year":"2000","journal-title":"Blood"},{"key":"2021063009510467900_CIT0035","doi-asserted-by":"crossref","first-page":"1242.e11","DOI":"10.1016\/j.amjmed.2014.07.010","article-title":"Incidence of Pneumocystis jirovecii pneumonia among groups at risk in HIV-negative patients","volume":"127","author":"Fillatre","year":"2014","journal-title":"Am J Med"},{"key":"2021063009510467900_CIT0036","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3201\/eid2009.131668","article-title":"Pneumocystis jirovecii pneumonia in patients with or without AIDS, France","volume":"20","author":"Roux","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2021063009510467900_CIT0037","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.2820360912","article-title":"Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis","volume":"36","author":"Hughes","year":"1975","journal-title":"Cancer"},{"key":"2021063009510467900_CIT0038","first-page":"337","article-title":"[Pneumocystis carinii infection in children with acute leukemia and non-Hodgkin malignant lymphoma.]","volume":"58","author":"Cyklis","year":"1983","journal-title":"Pediatr Pol"},{"key":"2021063009510467900_CIT0039","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM197712292972602","article-title":"Successful chemoprophylaxis for Pneumocystis carinii pneumonitis","volume":"297","author":"Hughes","year":"1978","journal-title":"N Engl J Med"},{"key":"2021063009510467900_CIT0040","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-104-3-338","article-title":"Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy","volume":"104","author":"Browne","year":"1986","journal-title":"Ann Intern Med"},{"key":"2021063009510467900_CIT0041","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ajh.2830490207","article-title":"Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis","volume":"49","author":"Byrd","year":"1995","journal-title":"Am J Hematol"},{"key":"2021063009510467900_CIT0042","first-page":"1283","article-title":"The value of Pneumocystis carinii antibody and antigen detection for diagnosis of Pneumocystis carinii pneumonia after marrow transplantation","volume":"120","author":"Meyers","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"2021063009510467900_CIT0043","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1164\/ajrccm\/137.6.1268","article-title":"Unexpectedly high incidence of Pneumocystis carinii infection after lung-heart transplantation: implications for lung defense and allograft survival","volume":"137","author":"Gryzan","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"2021063009510467900_CIT0044","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0002-9343(93)90187-T","article-title":"Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors","volume":"94","author":"Slivka","year":"1993","journal-title":"Am J Med"},{"key":"2021063009510467900_CIT0045","first-page":"41","article-title":"Pneumocystis pneumonia in patients with cancer: clinical setting","volume":"43","author":"DeVita","year":"1976","journal-title":"Natl Cancer Inst Monogr"},{"key":"2021063009510467900_CIT0046","doi-asserted-by":"crossref","first-page":"S416","DOI":"10.1093\/clinids\/17.Supplement_2.S416","article-title":"Pneumocystis carinii pneumonia in patients without AIDS","volume":"17","author":"Sepkowitz","year":"1993","journal-title":"Clin Infect Dis"},{"key":"2021063009510467900_CIT0047","doi-asserted-by":"crossref","first-page":"223","DOI":"10.7326\/0003-4819-111-3-223","article-title":"CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection","volume":"111","author":"Masur","year":"1989","journal-title":"Ann Intern Med"},{"key":"2021063009510467900_CIT0048","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12651","article-title":"The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: a systematic review","volume":"19","author":"Messiaen","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"2021063009510467900_CIT0049","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000487713","article-title":"Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia","volume":"96","author":"Salzer","year":"2018","journal-title":"Respiration"},{"key":"2021063009510467900_CIT0050","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/14787210.2019.1671823","article-title":"Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients","volume":"17","author":"Cill\u00f3niz","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2021063009510467900_CIT0051","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pulmoe.2019.04.003","article-title":"Pneumocystosis pneumonia: a comparison study between HIV and non-HIV immunocompromised patients","volume":"25","author":"Rego de Figueiredo","year":"2019","journal-title":"Pulmonology"},{"key":"2021063009510467900_CIT0052","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1399-3062.2012.00739.x","article-title":"Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons","volume":"14","author":"McKinnell","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"2021063009510467900_CIT0053","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2141.2002.03419.x","article-title":"Pneumocystis carinii pneumonia in patients with malignant haematologic diseases: 10 years\u2019 experience of infection in GIMEMA centres","volume":"117","author":"Pagano","year":"2002","journal-title":"Br J Haematol"},{"key":"2021063009510467900_CIT0054","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.12-0477","article-title":"Pneumocystis pneumonia in patients treated with rituximab","volume":"144","author":"Martin-Garrido","year":"2013","journal-title":"Chest"},{"key":"2021063009510467900_CIT0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4067\/S0716-10182014000400007","article-title":"[Pneumocystis jiroveci pneumonia: comparative study of cases in HIV-infected patients and immunocompromised non-HIV-infected patients.]","volume":"31","author":"Cer\u00f3n","year":"2014","journal-title":"Rev Chilena Infectol"},{"key":"2021063009510467900_CIT0056","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jiac.2014.03.003","article-title":"Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients","volume":"20","author":"Kofteridis","year":"2014","journal-title":"J Infect Chemother"},{"key":"2021063009510467900_CIT0057","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.medmal.2011.07.006","article-title":"Pneumocystis jirovecii colonization and infection among non HIV-infected patients","volume":"41","author":"Fily","year":"2011","journal-title":"Med Mal Infect"},{"key":"2021063009510467900_CIT0058","doi-asserted-by":"crossref","first-page":"e101943","DOI":"10.1371\/journal.pone.0101943","article-title":"Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: a retrospective study of two centers in China","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS One"},{"key":"2021063009510467900_CIT0059","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jmii.2012.08.024","article-title":"Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV \u2013infected individuals","volume":"47","author":"Li","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"2021063009510467900_CIT0060","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jcrc.2013.12.005","article-title":"Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients","volume":"29","author":"Ko","year":"2014","journal-title":"J Crit Care"},{"key":"2021063009510467900_CIT0061","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1465-9921-14-87","article-title":"Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia","volume":"14","author":"Lemiale","year":"2013","journal-title":"Respir Res"},{"key":"2021063009510467900_CIT0062","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.ejrad.2011.02.052","article-title":"HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients","volume":"81","author":"Vogel","year":"2012","journal-title":"Eur J Radiol"},{"key":"2021063009510467900_CIT0063","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.diii.2012.04.021","article-title":"Lung infections: the radiologist\u2019s perspective","volume":"93","author":"Beigelman-Aubry","year":"2012","journal-title":"Diagn Interv Imaging"},{"key":"2021063009510467900_CIT0064","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejrad.2019.04.025","article-title":"Pneumocystis jirovecii pneumonia at chest high-resolution computed tomography (HRCT) in non-HIV immunocompromised patients: spectrum of findings and mimickers","volume":"116","author":"Cereser","year":"2019","journal-title":"Eur J Radiol"},{"key":"2021063009510467900_CIT0065","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3201\/eid1910.121836","article-title":"Antibody responses against Pneumocystis jirovecii in health care workers over time","volume":"19","author":"Fong","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"2021063009510467900_CIT0066","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12281-014-0188-8","article-title":"Update on diagnosis of Pneumocystis pulmonary infections","volume":"8","author":"Rath","year":"2014","journal-title":"Curr Fungal Infect Rep"},{"key":"2021063009510467900_CIT0067","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/eri.10.42","article-title":"Pneumocystis infection in humans: diagnosis and treatment","volume":"8","author":"Calder\u00f3n","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2021063009510467900_CIT0068","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJM198803103181001","article-title":"Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies","volume":"318","author":"Kovacs","year":"1988","journal-title":"N Engl J Med"},{"key":"2021063009510467900_CIT0069","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/00313029400169761","article-title":"An evaluation of four methods for the detection of Pneumocystis carinii in clinical specimens","volume":"26","author":"Tiley","year":"1994","journal-title":"Pathology"},{"key":"2021063009510467900_CIT0070","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1093\/jac\/dkw156","article-title":"ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Alanio","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021063009510467900_CIT0071","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1128\/JCM.01480-14","article-title":"Diagnosis of Pneumocystis jirovecii pneumonia in immunocompromised patients by real-time PCR: a 4-year prospective study","volume":"52","author":"Robert-Gangneux","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2021063009510467900_CIT0072","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1099\/jmm.0.001190","article-title":"Ability of quantitative PCR to discriminate Pneumocystis jirovecii pneumonia from colonization","volume":"69","author":"Perret","year":"2020","journal-title":"J Med Microbiol"},{"key":"2021063009510467900_CIT0073","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/jof6010009","article-title":"Quantification of Pneumocystis jirovecii: cross-platform comparison of one qPCR assay with leading platforms and six master mixes","volume":"6","author":"Delli\u00e8re","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"2021063009510467900_CIT0074","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/mmy\/myz115","article-title":"The Fungal PCR Initiative\u2019s evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: toward a standard for a diagnostics assay","volume":"58","author":"Gits-Muselli","year":"2019","journal-title":"Med Mycol"},{"key":"2021063009510467900_CIT0075","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1469-0691.2010.03400.x","article-title":"Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients","volume":"17","author":"Alanio","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2021063009510467900_CIT0076","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1086\/588295","article-title":"Reappraisal of the serum (1\u2013&gt;3)-beta-D-glucan assay for the diagnosis of invasive fungal infections\u2014a study based on autopsy cases from 6 years","volume":"46","author":"Obayashi","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021063009510467900_CIT0077","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1128\/JCM.05267-11","article-title":"Diagnostic accuracy of serum 1,3-\u03b2-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis","volume":"50","author":"Onishi","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2021063009510467900_CIT0078","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/1040841X.2010.484001","article-title":"Pneumocystis jirovecii infection: cell wall (1\u21923)-\u03b2;-D-glucan biology and diagnostic utility","volume":"36","author":"Finkelman","year":"2010","journal-title":"Crit Rev Microbiol"},{"key":"2021063009510467900_CIT0079","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cmi.2020.05.024","article-title":"Diagnostic accuracy of serum (1-3)-\u03b2-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis","volume":"26","author":"Del Corpo","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2021063009510467900_CIT0080","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jiac.2014.07.001","article-title":"Serum (1 \u2192 3) \u03b2-D-glucan assay for discrimination between Pneumocystis jirovecii pneumonia and colonization","volume":"20","author":"Tasaka","year":"2014","journal-title":"J Infect Chemother"},{"key":"2021063009510467900_CIT0081","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/JCM.01554-13","article-title":"Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1-&gt;3)-\u03b2-D-glucan for differential diagnosis of pneumocystis pneumonia and Pneumocystis colonization","volume":"51","author":"Damiani","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2021063009510467900_CIT0082","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/cid\/ciy1072","article-title":"Clinical performance of (1,3) Beta-D glucan for the diagnosis of pneumocystis pneumonia (PCP) in cancer patients tested with PCP polymerase chain reaction","volume":"69","author":"Morjaria","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021063009510467900_CIT0083","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/myc.12997","article-title":"Combination of \u03b2-(1,3)-D-glucan testing in serum and qPCR in nasopharyngeal aspirate for facilitated diagnosis of Pneumocystis jirovecii pneumonia","volume":"62","author":"Desoubeaux","year":"2019","journal-title":"Mycoses"},{"key":"2021063009510467900_CIT0084","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jiac.2019.05.007","article-title":"Serial change in serum biomarkers during treatment of non-HIV pneumocystis pneumonia","volume":"25","author":"Urabe","year":"2019","journal-title":"J Infect Chemother"},{"key":"2021063009510467900_CIT0085","doi-asserted-by":"crossref","first-page":"e00322-19","DOI":"10.1128\/JCM.00322-19","article-title":"Beta-d-glucan for diagnosing pneumocystis pneumonia: a direct comparison between the Wako \u03b2-glucan assay and the Fungitell assay","volume":"57","author":"Mercier","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2021063009510467900_CIT0086","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/cid\/cir897","article-title":"\u03b2-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3)","volume":"54","author":"Lamoth","year":"2012","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/Supplement_2\/S114\/38840547\/ciaa1805.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/Supplement_2\/S114\/38840547\/ciaa1805.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T22:12:12Z","timestamp":1669932732000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/Supplement_2\/S114\/6168269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":86,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2021,3,12]]},"published-print":{"date-parts":[[2021,3,12]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1805","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,15]]},"published":{"date-parts":[[2021,3,12]]}}}